key: cord-0823554-qczjm0vo
authors: Kaufeld, J.K.; Reinhardt, M.; Schröder, C.; Bräsen, J.H.; Wiech, T.; Brylka, P.; Khaled, A.; Bergmann, C.; Haller, H.; Gäckler, A.; Schmidt, B.M.W.
title: Atypical HUS triggered by infection with SARS-CoV2
date: 2021-07-08
journal: Kidney Int Rep
DOI: 10.1016/j.ekir.2021.07.004
sha: 5ccf7989b15a128df199e85bd35871cb15e98796
doc_id: 823554
cord_uid: qczjm0vo

nan

Atypical haemolytic and uremic syndrome (aHUS) as a form of thrombotic microangiopathy (TMA) is characterized by a genetic or acquired dysregulation of complement activation leading to endothelial cell lesions and thrombosis of the small vessels, haemolysis, thrombocytopenia, and acute kidney injury S1 .

Here, we report two cases of complement mediated aHUS triggered by infection with SARS-CoV-2.

A 22-year-old female was travelling abroad in early January 2021 to visit her boyfriend.

Returning to Germany a mandatory SARS-CoV2 antigen-test was performed. The antigen test and a subsequent PCR-test showed SARS-CoV-2 infection. Albeit no symptoms of a respiratory tract infection were present, she had to see her general practitioner (GP) due to diarrhoea with persistent vomiting and loss of taste. As the condition did not improve she presented to the emergency department of another hospital 4 days after she had returned from her trip. Physical examination revealed a normotensive, alert and oriented patient who was pale and in acute distress.

The laboratory findings at admission revealed a thrombocytopenia with 28,000/µl. During the first days of admission the patient received 5 packed red blood cell transfusions due to ongoing haemolysis. The detection of schistocytes on peripheral blood smear confirmed thrombotic microangiopathy and daily plasma exchange using fresh frozen plasma as substitution solution was initiated. After exclusion of ADAMTS13 deficiency the diagnosis of aHUS was made, plasma exchange treatment was stopped after the third session and treatment with the C5-inhibitor eculizumab was initiated. A renal biopsy confirming TMA was performed at day 9 after admission, which was complicated by a postinterventional bleeding which was treated by endovascular coiling (Figure 1 ). Platelet count normalized and haemolysis resolved during the first 10 days (Figure 2a ). Hemodialysis treatment could be tapered and finally stopped. Notably, the ct value of this patient had already increased to over 35 before plasma exchange was initiated, marking the serologic recovery from SARS-CoV-2 before treatment for aHUS was initiated. During follow up, the likely pathogenic CFH (complement factor H) splice variant c.3493+5G>A (chr1:g.196715134G>A) was identified that affects a highly conserved residue and is predicted to be pathogenic by all eight bioinformatics prediction tools used. The change is not reported in any database (gnomAD minor allele frequency/MAF 0%) and has not been described in the literature so far. Internally, we have already detected this variant in our lab in one of our patients who demonstrated a similar phenotype and did not bear another variant of (likely) pathogenic character. Conclusively, it is most likely that the above CFH variant was causative in our patient.

A 52-year-old female with a history of mild hypertension saw her GP due to flu-like symptoms, loss of taste and exhaustion. The GP initiated antibiotic treatment with amoxicillin. Ten days later the patient returned to the GP with additional abdominal pain and Initial laboratory findings:

Laboratory findings at admission revealed a haemoglobin level of 9.4 g/dl, elevation of LDH to 885 U/l and acute kidney injury (KDIGO 1) with a serum creatinine of 2.9 mg/dl (255 µmol/l). Interestingly, platelets were normal with 318,000/µl, but were reported to have been "unusually high" in the past (>400,000/µl).

During the following days the patient developed progressive haemolytic anaemia with detection of schistocytes on peripheral blood smear and platelets decreased to a minimum of 128,000/µl. Due to progressive renal injury a renal biopsy was performed four days after admission, which was complicated by a post-interventional bleeding with transfusion of four packed red blood cell concentrates. Hemodialysis treatment was started ten days after admission due to volume overload. Renal biopsy showed fibrin-rich glomerular and preglomerular thrombotic microangiopathy (Supplementary Figure S1 ). As ADAMTS13 deficiency had already been excluded (activity 36%), diagnosis of aHUS was made and treatment with the C5-inhibitor eculizumab was initiated. Platelets increased to a maximum of 531,000/µl and haemolysis resolved within 13 days (Figure 2b Here, we present two cases of female patients with first aHUS episodes after infection with SARS-CoV-2 and recovering from COVID-19 disease, who were successfully treated with eculizumab. In our patients, these episodes mark the first manifestations of aHUS. A pathogenic complement factor H mutation was found in both women presenting as young to middle-age adults. In conclusion, our case reports underline that an infection with SARS-CoV-2 should be recognized as a potent trigger in patients with inherent complement defects, even when the symptoms of infection were mild or the patient has recovered from COVID-19 disease.

Clinical and laboratory findings suspicious of haemolytic anaemia with/or thrombopenia should prompt further diagnostic workup regarding thrombotic microangiopathies ( Table 1) .

Cases of unexplained thrombocytopenia as well as aHUS-like syndromes have been reported after vaccination against SARS-CoV-2 6,7 . Vaccination against or infection with SARS-CoV- 1= platelets (*10^3/µl), 2= creatinine (µmol/l), 3= lactic dehydrogenase (U/dl), 4= hemoglobin (g/dl),PE= plasma exchange, Ec= eculizumab, IHD= Intermittent hemodialysis 

The case of complement activation inCOVID-19 multiorgan impact

Complement C5inhibition in patients with COVID-19 -a promising target?

Direct activation of the alternative complement pathway by SARS-CoV-2 spike proteins is blocked by factor D inhibition

Atypical HUS relapse triggered by COVID-19

Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults

CoViD vaccines and thrombotic events: EMA issued warning to patients and healthcare professionals

Prothrombotic immune thrombocytopenia after COVID-19 vaccine

Minimal change disease relapse following SARS-CoV-2 mRNA vaccine

Gross hematuria following vaccination for severe acute respiratory syndrome coronavirus 2 in 2 patients with IgA nephropathy

Atypical hemolytic uremic syndrome (aHUS) is a rare disease characterized by microangiopathic hemolytic anemia, thrombocytopenia and organ involvement (mainly acute renal injury)

aHUS results from excessive complement activation causing endothelial damage which can be treated by therapeutic complement inhibition

Several "triggers" have been identified to induce complement activation such as infections, arterial hypertension, malignancies, transplantation, pregnancy, or systemic diseases

Genetic alterations (when classified as pathologic) in complement regulating genes make patients more susceptible for aHUS episodes, especially when being exposed to a "trigger

1: Renal biopsy of first case. Representative micrograph of thrombotic microangiopathy revealing several glomerular thrombi (arrowheads), one of them extending from ectatic preglomerular arteriole into the glomerulum. Additionally, mesangiolysis with fibrillar appearance of mesangial tissue containing red blood cell fragments can be seen (arrow)

The study was supported by the DEFEAT Pandemics platform of the Federal Ministry of Education and Research (BMBF) to TW. All other authors have nothing to disclose.

The authors declare that they have obtained consent from the patients discussed in this report.

Supplementary information is available at KI Report's website.1. Supplementary References S1-S4, (PDF) 2. Supplementary figure S1: Renal biopsy of second case (PPT)